Enrolling

A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3

J4G-OX-JZVA -

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435.

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Bladder Cancer, Advanced Solid Tumors
What the trial is testing?
LOX-24350 / LOXO-435, Pembrolizumab
Could I receive a Placebo?
No
Enrollment Goal
180
Trial Dates
Jan 12, 2023 - Jun 2025
How long will I be in the trial?
Your participation in this trial could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have solid tumor cancer with a change in the FGFR3 gene

  • Cancer must be advanced or has spread to another part(s) of the body

  • Have stopped all cancer treatment and have recovered from the major side effects

  • Have blood test results that show that organs are working adequately

Participants Must Not:

  • Have a serious disorder of the eye

  • Have an active infection

  • Have cancer that began in the brain or spread to the brain and is causing symptoms

  • Have a serious heart condition

  • Patients who are pregnant, lactating, or plan to breastfeed during the study or within 6 months of the last dose of study treatment

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources